Skip to main content

User menu

  • Sign in
  • Register

Main menu

  • Pfizer Medicines
  • Therapy Areas
  • News
  • Materials
  • Useful Links

Search form

Pfizer Home
  • Inflectra® (Infliximab)

Clinical Information

  • Rheumatoid arthritis
    • Inflectra® | Contraindications and Safety Information
    • Inflectra® | Dosing
    • Inflectra® | Safety Profile & Efficacy
  • Adult Crohn's disease
  • Ulcerative colitis

Useful Resources

  • About Inflectra®
  • Biosimilars
  • Considerations for Biologic Switching
  • Extrapolation
  • GECSE KB, et al 2017
  • Induction and Maintenance in IBD
  • Inflammatory Bowel Disease
  • NOR-SWITCH
  • Optimising Treatment with Inflectra®
  • PLANETAS
  • PLANETRA
  • PROSIT-BIO
  • Paediatric Studies
  • Real World Evidence in IBD
  • Study 3.4
  • Switch Studies
  • UK Guidance on Biosimilars
  • Clinical References

This site is intended only for healthcare professionals resident in the United Kingdom

Other indications
Inflectra® is a biosimilar of infliximab, a monoclonal antibody, used in the treatment of Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and severe plaque psoriasis.

Inflectra® | Dosing

Dosing in Rheumatoid Arthritis (RA)

Inflectra® dosing is based on a patient's disease, weight and condition2.

Inflectra Dosing: Rheumatoid Arthritis

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

PP-IFA-GBR-0286. December 2018

Pfizer Home
  • Inflectra® (Infliximab)

Clinical Information

  • Rheumatoid arthritis
    • Inflectra® | Contraindications and Safety Information
    • Inflectra® | Dosing
    • Inflectra® | Safety Profile & Efficacy
  • Adult Crohn's disease
  • Ulcerative colitis

Useful Resources

  • About Inflectra®
  • Biosimilars
  • Considerations for Biologic Switching
  • Extrapolation
  • GECSE KB, et al 2017
  • Induction and Maintenance in IBD
  • Inflammatory Bowel Disease
  • NOR-SWITCH
  • Optimising Treatment with Inflectra®
  • PLANETAS
  • PLANETRA
  • PROSIT-BIO
  • Paediatric Studies
  • Real World Evidence in IBD
  • Study 3.4
  • Switch Studies
  • UK Guidance on Biosimilars
  • Clinical References
Optimising Treatment with Inflectra®
Optimising Treatment with Inflectra®
Learn more about TDM and biomarkers
Help manage your patients with IBD
Help manage your patients with IBD
Find out more about Inflectra® for UC and CD
UK and European Guidance on Biosimilar Infliximab
UK and European Guidance on Biosimilar Infliximab
Read more on NICE, BSR, BSG and ECCO Position Statements

Janrain Capture

  • Register / Sign in

Footer menu

  • Report Adverse Events
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Pfizer.co.uk

Copyright footer block

Copyright © 2016-2020 Pfizer Limited. All rights reserved.
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427.
This site is intended only for healthcare professional’s resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
PP-PFE-GBR-2464. April 2020

For healthcare professionals only*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select ‘No’, you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer’s prescription medicines.

*The ABPI Code definition of healthcare professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-GIP-GBR-3015 March 2018

YesNo
Your login attempt failed. Please try again.

{* message_withExistingAccount *}

{* loginWidget *}

{* message_joinNow *}

{* message_joinNowText *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* traditionalSignIn_createButton *}

{* message_signIn *}

Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* loginWidget *}
{* message_useAnotherAccount *}
Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* message_useAnotherAccount *}

{* message_registeringThankYou *}

{* message_confirmEmailSent *}

{* message_close *}

{* message_confirmTraditionalInformation *} {* message_alreadyHaveAccount *}

* Required Information

{* #registrationForm *} {* salutation *} {* givenName *} {* familyName *} {* email *} {* designation_name *} {* designation_specialty *} {* designation_specialty2 *} {* designation_specialty_json *} {* primaryAddress_workplace *} {* primaryAddress_postalCode *} {* phoneNumber_work *} {* license_number *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* acknowledgement_professional *} {* acknowledgement_consent *} {* acknowledgement_terms *}
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
{* hidden_programType *} {* hidden_campaign *} {* hidden_siteId *} {* hidden_preferredLanguage *} {* hidden_residencyCountry *}

PP-PFE-GBR-2353. March 2020
{* backButton *}
{* createAccountButton *}
{* /registrationForm *}
{*#postLoginAcceptanceForm*}

{* message_legalText *}

{* postLoginAcceptanceButton *}
{*/postLoginAcceptanceForm*}

{* message_emailPasswordResetInstructions *}

{* #forgotPasswordForm *} {* traditionalSignIn_emailAddress *}
{* backButton *}
{* forgotPassword_sendButton *}
{* /forgotPasswordForm *}

{* message_emailPasswordResetSent *}

{* message_close *}
{* mergeAccounts *}
{* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *}
{* backButton *}
{* traditionalSignIn_signInButton *}
{* /tradAuthenticateMergeForm *}